🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A high fiber dietary intervention significantly improved response to immunotherapy in patients with melanoma receiving immune checkpoint blockade therapy. Our postdoctoral fellow Dr. Yufan Simon Qiu shared results at #ASCO25. Learn more: bit.ly/4mGk4pO Nazli Dizman

Multicancer early detection tests are gaining attention, especially as 50% of cancer types don't have an early detection method. At #ASCO25, Dr. Jennifer Litton discussed which endpoints could support wider adoption of these tests in everyday care. #EndCancer Jennifer Litton

“Ensuring adequate quality data and leveraging the right AI model for the task are critical parts of responsible AI use,” says our Dr. Caroline Chung at #ASCO25. “We all need to do our due diligence on AI literacy to equip ourselves and the next generation.” @CA_Chung ASCO

Our Dr. Funda Meric-Bernstram gave a deep-dive on bispecifics and tyrosine kinase inhibitors in combination therapy to a full room at #ASCO25. ASCO #EndCancer

Fertility preservation is a key concern for many women with cancer, yet it’s often overlooked. Dr. Terri Woodard highlights the need to address this early in treatment planning. Timely referral to a reproductive specialist can ease distress and expand options. #ASCO25 #EndCancer

Dr. Eric Singhi shares his excitement about the lung cancer research being presented at #ASCO25. Hear how this year’s meeting highlights the continued momentum in advancing the field and improving patient outcomes. #EndCancer Eric K. Singhi, MD

New data from the CADENZA study shows pivekimab sunirine (PVEK) led to a 70% CR + CRc rate in frontline BPDCN with a manageable safety profile. Presented by Dr. Naveen Pemmarju at #ASCO25. #EndCancer bit.ly/45E62i9 Naveen Pemmaraju, MD

Early results show encouraging efficacy of a novel triplet combo of cladribine, venetoclax, and alternating azacitidine and low-dose cytarabine in patients with higher-risk MDS and CMML, presented by our Dr. Guillermo Montalban-Bravo at #ASCO25. Read more: bit.ly/43AMrN8 ASCO